EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak ...
Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...
A statistically significant reduction from baseline in Valsalva LVOT gradient was observed with mavacamten vs placebo at week 28. Topline data were announced from a phase 3 trial evaluating mavacamten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results